Xenetic Biosciences Presents Case Study of PolyXen™ Platform Technology at the 13th Annual Protein Engineering Summit (PEGS) Boston
Xenetic Biosciences’ PolyXen™ Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston
Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer
Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update
Xenetic Biosciences to Ring Nasdaq Stock Market Opening Bell on March 30, 2017
Xenetic Biosciences Provides Update on Patent Portfolio Development
Xenetic Biosciences to Present at the 29th Annual ROTH Conference
Xenetic Biosciences Receives $3 Million Milestone Payment from Shire plc for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia
Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer
